A Phase 2 proof of concept study of MRT 6160 in multiple autoimmune diseases
Latest Information Update: 10 Jan 2024
At a glance
- Drugs MRT 6160 (Primary)
- Indications Autoimmune disorders
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 10 Jan 2024 New trial record
- 08 Jan 2024 According to a Monte Rosa Therapeutics media release, a Phase 1 study of MRT-6160 in healthy volunteer is supporting potential future for Phase 2 proof-of-concept studies in multiple autoimmune diseases.